AZT exerts its antitumoral effect by telomeric and non-telomeric effects in a mammary adenocarcinoma model

Oncology Reports

Volumn 36, Issue 5, 2016, Pages 2731-2736

  Armando, Romina G ^a   Gomez, Diego Mengual ^a   Gomez, Daniel E ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

AZT; C Myc; Cancer; Cyc D; Telomerase; Tert

Indexed keywords

BETA CATENIN; CYCLIN D1; MYC PROTEIN; TELOMERASE; WNT PROTEIN; ZIDOVUDINE; MYC PROTEIN, HUMAN; TERT PROTEIN, MOUSE;

ACTIN FILAMENT; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; F3II CELL LINE; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TELOMERE; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL DIVISION; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; PATHOLOGY; TELOMERE HOMEOSTASIS; WNT SIGNALING PATHWAY;

ACTIN CYTOSKELETON; ADENOCARCINOMA; ANIMALS; APOPTOSIS; BETA CATENIN; BREAST NEOPLASMS; CELL DIVISION; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN D1; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; TELOMERASE; TELOMERE HOMEOSTASIS; WNT SIGNALING PATHWAY; ZIDOVUDINE;

EID: 84989875885     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.5094     Document Type: Article

References (28)

1. Terali K and Yilmazer A: New surprises from an old favourite: The emergence of telomerase as a key player in the regulation of cancer stemness. Biochimie 121: 170-178, 2016.
2. Martínez P and Blasco MA: Replicating through telomeres: A means to an end. Trends Biochem Sci 40: 504-515, 2015.
3. Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS, Ghiringhelli PD and Alonso DF: Telomere structure and telomerase in health and disease (Review). Int J Oncol 41: 1561-1569, 2012.
4. Hájek M, Matulová N, Votruba I, Holý A and Tloust'ová E: Inhibition of human telomerase by diphosphates of acyclic nucleoside phosphonates. Biochem Pharmacol 70: 894-900, 2005.
5. Gomez D, Kassim A and Olivero O: Preferential incorporation of 3'-azido-2',3'-dideoxythymidine (azt) in telomeric sequences of cho cells. Int J Oncol 7: 1057-1060, 1995.
6. Gomez DE, Tejera AM and Olivero OA: Irreversible telomere shortening by 3'-azido-2',3'-dideoxythymidine (AZT) treatment. Biochem Biophys Res Commun 246: 107-110, 1998.
7. Tejera AM, Alonso DF, Gomez DE and Olivero OA: Chronic in vitro exposure to 3'-azido-2', 3'-dideoxythymidine induces senescence and apoptosis and reduces tumorigenicity of metastatic mouse mammary tumor cells. Breast Cancer Res Treat 65: 93-99, 2001.
8. Koh CM, Khattar E, Leow SC, Liu CY, Muller J, Ang WX, Li Y, Franzoso G, Li S, Guccione E, et al: Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J Clin Invest 125: 2109-2122, 2015.
9. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, et al: Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460: 66-72, 2009.
10. Martínez P and Blasco MA: Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 11: 161-176, 2011.
11. De Leonardis F, Monti L, Gualeni B, Tenni R, Forlino A and Rossi A: Altered signaling in the G1 phase deregulates chondrocyte growth in a mouse model with proteoglycan undersulfation. J Cell Biochem 115: 1779-1786, 2014.
12. Li Y, Casey SC and Felsher DW: Inactivation of MYC reverses tumorigenesis. J Intern Med 276: 52-60, 2014.
13. Alonso DF, Farías EF, Urtreger A, Ladeda V, Vidal MC and Bal De Kier Joffé E: Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. J Surg Oncol 62: 288-297, 1996.
14. Segatori VI, Otero LL, Fernandez LE, Gomez DE, Alonso DF and Gabri MR: Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides. In Vivo 26: 609-617, 2012.
15. Chen YY, Wu XQ, Tang WJ, Shi JB, Li J and Liu XH: Novel dihydropyrazole-chromen: Design and modulates hTERT inhibition proliferation of MGC-803. Eur J Med Chem 110: 65-75, 2016.
16. Gomez DE, Armando RG and Alonso DF: AZT as a telomerase inhibitor. Front Oncol 2: 113, 2012.
17. Ji HJ, Rha SY, Jeung HC, Yang SH, An SW and Chung HC: Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res Treat 93: 227-236, 2005.
18. Jin RR, Chao R, Xi YM, Chen C, Chu HY, Li M and Zhang H: Effects of AZT on leukemia cell line KG-1a proliferation and telomerase activity. Zhongguo Shi Yan Xue Ye Xue Za Zhi 20: 277-281, 2012.
19. Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O and Nicot C: Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108: 1021-1029, 2006.
20. Fang JL, McGarrity LJ and Beland FA: Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells. Mutagenesis 24: 133-141, 2009.
21. Olivero OA, Tejera AM, Fernandez JJ, Taylor BJ, Das S, Divi RL and Poirier MC: Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 20: 139-146, 2005.
22. Bretones G, Delgado MD and León J: Myc and cell cycle control. Biochim Biophys Acta 1849: 506-516, 2015.
23. Hassani S, Ghaffari SH, Zaker F, Mirzaee R, Mardani H, Bashash D, Zekri A, Yousefi M, Zaghal A, Alimoghaddam K, et al: Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest. Ann Hematol 92: 1207-1220, 2013.
24. Abbas T and Dutta A: p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer 9: 400-414, 2009.
25. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, Prochownik EV and Nikiforov MA: c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 27: 1905-1915, 2008.
26. Chen D, Huang J, Zhang K, Pan B, Chen J, De W, Wang R and Chen L: MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur J Cancer 50: 3050-3067, 2014.
27. Shi JW, Liu W, Zhang TT, Wang SC, Lin XL, Li J, Jia JS, Sheng HF, Yao ZF, Zhao WT, et al: The enforced expression of c-Myc in pig fibroblasts triggers mesenchymal-epithelial transition (MET) via F-actin reorganization and RhoA/Rock pathway inactivation. Cell Cycle 12: 1119-1127, 2013.
28. Bhushan B and Kush L: Pharmocophoric studies of anti-telomerase drugs. Int J Innov Res Dev 3: 268-272, 2014.